Kane Biotech Announces Loan Transaction
December 29, 2022 17:34 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has reached an agreement to obtain loans...
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
December 28, 2022 16:30 ET
|
Cellectis Inc.
The credit facility will enable Cellectis to support the development of its UCART product candidates pipelineThe credit facility consists of three tranches of €20 million, €15 million, and €5 million...
Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2- Breast Cancer Therapy with End-to-End AI Engine
December 27, 2022 12:30 ET
|
InSilico Medicine
New York, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company's...
Persbericht Biocartis Group NV: Openbaarmaking van een transparantiekennisgeving
December 22, 2022 11:45 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE22 december 2022, 17:45 CET Openbaarmaking van een transparantiekennisgeving Mechelen, België, 22 december 2022 – Biocartis Group NV (de...
Press release Biocartis Group NV: Disclosure of a transparency notification
December 22, 2022 11:45 ET
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION 22 December 2022, 17:45 CET Disclosure of a transparency notification Mechelen,...
Persbericht Biocartis Group NV: Openbaarmaking van uitstaande stemrechtverlenende effecten
December 22, 2022 11:40 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE22 december 2022, 17:40 CET Openbaarmaking van uitstaande stemrechtverlenende effecten Mechelen, België, 22 december 2022 – Biocartis Group NV...
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
December 22, 2022 11:40 ET
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION22 December 2022, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 22 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"),...
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
December 21, 2022 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
December 20, 2022 19:01 ET
|
Sosei Group Corporation
PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10...
Insilico Medicine Nominates Potential First-in-Class Preclinical Candidate with Novel AI-Designed Structure for Novel AI-Discovered Target in Immuno-oncology
December 20, 2022 09:00 ET
|
InSilico Medicine
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company...